The Centocor Ca 15-3 is a new in vitro test system for breast cancer patients utilizing two monoclonal antibodies which react with circulating antigen expressed by human breast carcinoma cells. Normal control persons demonstrated plasma values below 30 U/ml (median 14 U/ml). Pregnant women were found to have elevated levels 30-60 U/ml in 11,5% (3/20) of the cases, whereas in the amniotic fluid only normal values were measured.
In patients with ovarian cancer we observed in 9/12 (75%) cases in part extremely high (m700 U/ml) Bre 32 CA 15-3, A SPECIFIC TUMOUR MARKER FOR BREAST CANCER? G. P. Breitbach, L. J. Behnken*, N. Wieser*, H. Altholz CA 15-3 is supposed to be a circulating antigen expressed by human breast tumour cells. It can be detected by an available RIA-kit (Centocor), using 2 monoclonal antibodies against milk-fat globulin membranes (115 D 8) and a membrane-enriched fraction of human breast tumour tissue (DF 3). CA 15-3 plasma levels should serve as indicator and prognosis parameter for the follow-up for breast cancer patients.
To prove its validity we compared CA 15-3 plasma concentrations to CEA, TPA, CA 19-9 and CA 12-5 in the following test groups: a) breast tumours of unknown dignity pre-operatively, b) breast cancers in post-operative follow-up, c) metastatic breast cancers in treatment follow-up, d) other gynecologic cancer patients, e) breast-feeding patients and f) a control group with non-carcinomatous gynecologic diseases.
Up to Oct. 31, 1985, a number of 498 patients have been examined. Preliminary results show that only a small number (about I/3) of breast cancer patients show "positive" CA 15-3 levels before first treatment compared to the control group. In post-operative follow-up, CA 15-3 seems to be a good indicator for metastatic disease ("positive" levels in about 3/4 of the patients). The concentration of CA 15-3 seems to be dependant upon the tumour load. There were no "positive" CA 15-3 values in the breast-feeding group, instead, most of these patients showed positive TPA and CA 12-5 values. The investigations are in progress.
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